Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Derazantinib and Atezolizumab in Patients With Urothelial Cancer
Back

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

Completed

Open to: ALL

Age: 18.0 - N/A

Sutton London London London

Medical Conditions

Carcinoma, Transitional Cell

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study was to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic aberrations (GA) of various clinical stages of disease progression and prior treatments.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2019 Oct 2022

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Derazantinib was administered orally at a dose of 300 mg once daily

Intervention Arm Group : Substudy 1: Derazantinib 300 mg once daily;

Intervention Type : DRUG
Intervention Description : Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Intervention Arm Group : Substudy 2 (Dose-Level 1): Derazantinib 200 mg once daily + atezolizumab 1200 mg;

Intervention Type : DRUG
Intervention Description : Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Intervention Arm Group : Substudy 2 (Dose-Level 2): Derazantinib 300 mg once daily + atezolizumab 1200 mg;

Intervention Type : DRUG
Intervention Description : Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks

Intervention Arm Group : Substudy 3: Derazantinib 200 mg twice daily + atezolizumab 1200 mg;

Intervention Type : DRUG
Intervention Description : Derazantinib was administered orally at a dose of 300 mg once daily

Intervention Arm Group : Substudy 4 (Cohort 4a):Derazantinib 300 mg once daily;

Intervention Type : DRUG
Intervention Description : Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Intervention Arm Group : Substudy 4 (Cohort 4b):Derazantinib 300 mg once daily + atezolizumab 1200 mg;

Intervention Type : DRUG
Intervention Description : Derazantinib was administered orally at a dose of 200 mg twice daily

Intervention Arm Group : Substudy 5: Derazantinib 200 mg twice daily;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • The Royal Marsden NHS Foundation Trust
    Sutton
    SM2 5PT
  • Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)
    London
    EC1M 6BQ
  • The Sarah Cannon Research Institute
    London
    W1G 6AD
  • University College London Hospitals
    London
    W1T7HA


The study is sponsored by Basilea Pharmaceutica



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04045613
Last updated 21 September 2023

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top